Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Protein Design Labs Inc.

(PDLI)

Matthew Geller of Oppenheimer & Co. repeated a "buy" and raised his

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE